Global – USA Cancer Immunotherapy Market Analysis to two thousand twenty – Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the Top Five Cancer Drugs – Research and Markets, Business Wire
Global & USA Cancer Immunotherapy Market Analysis to two thousand twenty – Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the Top Five Cancer Drugs – Research and Markets
The “Global & USA Cancer Immunotherapy Market Analysis to two thousand twenty report exposes that the cancer immunotherapy space will be a significant revenue generator (excess of $80 billion) for the biopharmaceutical industry by 2020. The market has been supported by the approval of Bristol-Myers’ Yervoy drug for melanoma, BMS’s Opdivo and Merck’s Keytruda. Over the next decade, immunotherapies will be the backbone of cancer treatments in 60% of cancer types.
It is forecast that by 2020, Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the top five cancer drugs. A single drug, Bristol-Myers Squibb’s Yervoy, for example has earned revenues of about $960 million in two thousand thirteen and it is expected to have a market value of $1,775.Two million in 2020. Industry Experts have predicted that Keytruda and Opdivo will generate sales revenues of $Two.9 billion and $Four.Three billion respectively in 2019.
The interest on ADCs can be seen with the latest approvals of Adcetris (brentuximab vedotin) and Kadcyla (ado-trastuzumab emtansine). Presently, More than fifteen companies are developing thirty different ADCs targeting both hematologic malignancies and solid tumors. ADCs represent a novel class of therapeutic agents, gaining enhancing attention from both large and puny pharmaceutical companies.
As the ADCs carry a chemotherapy drug, they are believed to be more efficient and effective in the treatment of a disease. Due to shrinking pipelines and enlargening pressure from patent expirations, big pharmaco’ recognized the vaccine market as a potential resource for investors. Cancer vaccines have been found to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the request for these vaccines. The global market for cancer vaccines was worth about $Four.Four billion and it is likely to reach $8.Four billion in 2020.
- Antibody Drug Conjugates (ADCs)
- Bispecific Monoclonal Antibodies
- Cancer Vaccines
- Cytokines
- Interferons
- Chimeric Antigen Receptor (CAR) T-Cell Therapy
- PD-1/PD-L1 inhibitors
- Dendritic Cells
- Checkpoint Inhibitors
- Adopted Cell Therapy (ACT)
1. Executive Summary
Two. Cancer Immunotherapy: An Overview
Trio. Current Status of Cancer Immunotherapy: An Overview
Four. Challenges in Cancer Medicine Research: An Overview
Five. Cancer Immunotherapeutic Products: An Overview
6. Available Immunotherapies for Cancer by Disease Type: An Overview
7. Cancer Incidence and Mortality: An Overview
8. Market Analysis
9. Market for Cancer Immunotherapy
Ten. Company Profiles
11. Cancer Immunotherapy Market Participants by Product Segment
12. CAR T Therapy
13. Regulations Pertaining to Immunotherapy Regulation in the USA
14. Regulations for Immunotherapy in Japan
15. European Regulation and Immunotherapeutics
16. Manufacturing of Immunotherapies
17. Supply Chain & Logistics
Eighteen. Pricing & Cost Analysis
Nineteen. Current Deals Within the CAR T Market
Global – USA Cancer Immunotherapy Market Analysis to two thousand twenty – Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the Top Five Cancer Drugs – Research and Markets, Business Wire
Global & USA Cancer Immunotherapy Market Analysis to two thousand twenty – Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the Top Five Cancer Drugs – Research and Markets
The “Global & USA Cancer Immunotherapy Market Analysis to two thousand twenty report exposes that the cancer immunotherapy space will be a significant revenue generator (excess of $80 billion) for the biopharmaceutical industry by 2020. The market has been supported by the approval of Bristol-Myers’ Yervoy drug for melanoma, BMS’s Opdivo and Merck’s Keytruda. Over the next decade, immunotherapies will be the backbone of cancer treatments in 60% of cancer types.
It is forecast that by 2020, Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the top five cancer drugs. A single drug, Bristol-Myers Squibb’s Yervoy, for example has earned revenues of about $960 million in two thousand thirteen and it is expected to have a market value of $1,775.Two million in 2020. Industry Experts have predicted that Keytruda and Opdivo will generate sales revenues of $Two.9 billion and $Four.Trio billion respectively in 2019.
The interest on ADCs can be seen with the latest approvals of Adcetris (brentuximab vedotin) and Kadcyla (ado-trastuzumab emtansine). Presently, More than fifteen companies are developing thirty different ADCs targeting both hematologic malignancies and solid tumors. ADCs represent a novel class of therapeutic agents, gaining enlargening attention from both large and puny pharmaceutical companies.
As the ADCs carry a chemotherapy drug, they are believed to be more efficient and effective in the treatment of a disease. Due to shrinking pipelines and enhancing pressure from patent expirations, big pharmaco’ recognized the vaccine market as a potential resource for investors. Cancer vaccines have been found to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the request for these vaccines. The global market for cancer vaccines was worth about $Four.Four billion and it is likely to reach $8.Four billion in 2020.
- Antibody Drug Conjugates (ADCs)
- Bispecific Monoclonal Antibodies
- Cancer Vaccines
- Cytokines
- Interferons
- Chimeric Antigen Receptor (CAR) T-Cell Therapy
- PD-1/PD-L1 inhibitors
- Dendritic Cells
- Checkpoint Inhibitors
- Adopted Cell Therapy (ACT)
1. Executive Summary
Two. Cancer Immunotherapy: An Overview
Three. Current Status of Cancer Immunotherapy: An Overview
Four. Challenges in Cancer Medicine Research: An Overview
Five. Cancer Immunotherapeutic Products: An Overview
6. Available Immunotherapies for Cancer by Disease Type: An Overview
7. Cancer Incidence and Mortality: An Overview
8. Market Analysis
9. Market for Cancer Immunotherapy
Ten. Company Profiles
11. Cancer Immunotherapy Market Participants by Product Segment
12. CAR T Therapy
13. Regulations Pertaining to Immunotherapy Regulation in the USA
14. Regulations for Immunotherapy in Japan
15. European Regulation and Immunotherapeutics
16. Manufacturing of Immunotherapies
17. Supply Chain & Logistics
Eighteen. Pricing & Cost Analysis
Nineteen. Current Deals Within the CAR T Market
